| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 10 | 0 | 20 | 20 | 10 |
| Sales Growth | unch | -100.00% | unch | +100.00% | unch |
| Net Income | -9,010 | -8,450 | -14,400 | -6,540 | -8,150 |
| Net Income Growth | -6.63% | +41.32% | -120.18% | +19.75% | -3.56% |
Abliva Ab (NEVPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Abliva AB is a clinical-stage biotech company develops medicines for the treatment of primary mitochondrial diseases. Abliva AB, formerly known as NeuroVive Pharmaceutical AB, is based in Lund, Sweden.
Fiscal Year End Date: 12/31